Background: Recent studies suggest the involvement of the adenosine monophosphate-activated serine/threonine protein kinase (AMPK) pathway in the pathogenesis of diabetic nephropathy (DN). Resveratrol, an agent that activates AMPK, may have the potential to protect against the development of DN. This study was designed to investigate the therapeutic effects of resveratrol on renal hypertrophy in early-stage diabetes and the underlying mechanisms. Method: Molecular and structural changes involved in the pathogenesis of DN were tested in a rat model of early-stage diabetes. Renal mesangial cells (RMCs) were cultured in media containing different concentrations of glucose with or without resveratrol. Cellular DNA synthesis was assayed by measuring 3H-thymidine incorporation. The phosphorylation status of AMPK, eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), and phospho- ribosomal protein S6 (S6) was analyzed by Western blot. Results: Resveratrol reduced plasma creatinine and urinary albumin excretion and attenuated renal hypertrophy without affecting blood glucose levels. Moreover, resveratrol activated AMPK and inhibited phosphorylation of 4E-BP1 and S6 in diabetic rat kidneys. In vitro, resveratrol blocked high glucose-induced dephosphorylation of AMPK and phosphorylation of 4E-BP1 and S6 and strongly inhibited both the DNA synthesis and proliferation of RMCs. Conclusion: These findings suggest the possibility that resveratrol exerts antiproliferative, antihypertrophic effects by activating AMPK and reducing 4E-BP1 and S6 phosphorylation, thus suppressing the development and progression of DN.

Keywords:
Resveratrol, Diabetic nephropathy, Adenosine monophosphate-activated protein kinase, Renal mesangial cells, Hypertrophy, Eukaryotic translation initiation factor 4E binding protein 1, Phospho-ribosomal protein S6
1.
Mason RM, Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358–1373.
2.
Geoffroy K, Troncy L Wiernsperger N, Lagarde M, El Bawab S: Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett 2005;579:1249–1254.
3.
Towler MC, Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007;16:328–341.
4.
Shaw RJ: LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009;196:65–80.
5.
Motoshima H, Goldstein BJ, Igata M, Araki E: AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006;574:63–71.
6.
Ruderman N, Prentki M: AMP kinase and malonyl-CoA targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004;3:340–351.
7.
Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS: A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007;292:617–627.
8.
Harikumar KB, Aggarwal BB: Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008;7:1020–1035.
9.
Saiko P, Szakmary A, Jaeger W, Szekeres T: Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 2008;658:68–94.
10.
Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, Dyck JR: Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 2008;283:24194–24201.
11.
Bortolotti C, Kunit T, Moder A , Hufnagl C, Schmidt S, Hartl A, Langelueddecke C, Fürst J, Geibel JP, Ritter M, Jakab M: The phytostilbene resveratrol induces apoptosis in INS-1E rat insulinoma cells. Cell Physiol Biochem 2009;23:245–254.
12.
Lee MJ, Feliers D, Sataranatarajan K, Mariappan MM, Li M, Barnes JL, Choudhury GG, Kasinath BS: Resveratrol ameliorates high glucose-induced protein synthesis in glomerular epithelial cells. Cell Signal 2010;22:65–70.
13.
Lu Y, Liu C, Miao X, Xu K, Wu X, Liu C: Increased expression of myo-inositol oxygenase is involved in the tubulointerstitial injury of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2009;117:257–265.
14.
Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H: Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005;16:1013–1023.
15.
Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000;11:80–87.
16.
Buga GM, Frank JS, Mottino GA, Hakhamian A, Narasimha A, Watson AD, Yekta B, Navab M, Reddy ST, Anantharamaiah GM, Fogelman AM: D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J Lipid Res 2008;49:192–205.
17.
Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A: Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing strepto- zotocin induced type I diabetic nephropathy. Free Radic Res 2008;42:397–404.
18.
Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K: Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006;76:69–75.
19.
Venkatesan B, Ghosh-Choudhury N, Das F, Mahimainathan L, Kamat A, Kasinath BS, Abboud HE, Choudhury GG: Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J 2008;22:3469–3482.
20.
Dasgupta B, Milbrandt J: Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007;104:7217–7222.
21.
Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191–196.
22.
Borra MT, Smith BC, Denu JM: Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005;280:17187–17195.
23.
Chen JK, Chen J, Thomas G, Kozma SC, Harris RC: S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2009;297:585–593.
24.
Feliers D, Duraisamy S, Barnes JL, Ghosh-Choudhury G, Kasinath BS: Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II. Am J Physiol Renal Physiol 2004;288:521–529.
25.
Kueck A, Opipari AW Jr, Griffith KA, Tan L, Choi M, Huang J, Wahl H, Liu JR: Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol 2007;107:450–457.
26.
Haider UG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM: Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol Pharmacol 2002;62:772–777.
27.
Brito PM, Devillard R, Nègre-Salvayre A, Almeida LM, Dinis TC, Salvayre R, Auge N: Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis 2009;205:126–134.
28.
Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck JR: Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009;119:1643–1652.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.